Benzinga | Jul 20, 2020 05:10AM EDT

Credit Suisse Downgrades AcelRx Pharmaceuticals to Underperform, Lowers Price Target to $0.69

Credit Suisse analyst Evan Seigerman downgrades AcelRx Pharmaceuticals (NASDAQ:ACRX) from Neutral to Underperform and lowers the price target from $1 to $0.69.